2024 Labvocate Symposium September 30 to October 1 in Alexandria, Virginia, or virtual. Sign up by September 16!

News & Events

Society News Now

Laboratory Professionals Leadership Certificate Program on a laptop

Society News Now – August 2024

ASCLS submits comments and recommendations on the Standard Occupational Classification, new Laboratory Professionals Leadership Certificate Program, 2024 Labvocate Symposium early bird discount ends August 29, registration and travel scholarships available for Labvocate Symposium, opportunities to…

News Briefs

RSS ASCLS eNewsBytes

  • Kidney and liver transplants less common in patients with HIV September 3, 2024
    Low rates of kidney and liver transplantation occur among HIV-positive individuals, despite comparable post-operative outcomes. Expanding access to deceased and living donor kidney allografts and addressing ESKD or ESLD is needed.
  • Emergent Bio's smallpox vaccine gets US approval for mpox September 3, 2024
    The U.S. FDA has approved Emergent BioSolutions' new tab smallpox vaccine, making it the second approved shot against mpox in the U.S.. The vaccine, ACAM2000, uses a live, infectious form of the vaccinia virus, but cannot be administered to those with weakened immune systems.
  • Tiny test tubes sort stem cells for improved therapy September 3, 2024
    Researchers at the University of California, Los Angeles, have developed a method to identify subpopulations of mesenchymal stem cells secreting high levels of extracellular vesicles, potentially allowing for the selection of more therapeutically active cells for clinical applications.
  • Insect illnesses spike around the world September 3, 2024
    The spread of rare insect-borne diseases like eastern equine encephalitis and Oropouche fever is increasing due to global warming, longer, hotter summers and changes in land use. This has led to increased risks of dengue fever, West Nile Virus and malaria.
  • Inhibition of miR-10b treats metastatic breast cancer by targeting stem cell-like properties September 3, 2024
    The study presents a nanodrug, MN-anti-miR10b, which inhibits miR-10b, a key driver of metastatic breast cancer, and has shown to prevent metastasis and eliminate existing metastases in mice models, making it an effective treatment option for stem-like breast cancer.

Calendar